Login to Your Account



Novartis Takes Over Tyzeka For HBV

Idenix Restructures To Focus On Therapy Bids In HCV, HIV

By Randall Osborne


Monday, October 1, 2007
Idenix Pharmaceuticals Inc.'s layoff of about one-third of its work force could knock down the firm's burn rate by as much as half, as it retools the deal with Novartis AG for the approved hepatitis B drug Tyzeka and turns efforts toward early stage compounds for hepatitis C virus and HIV. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription